Issa F. Khouri

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

74h-index19.9kcitations600works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hematopoietic Stem Cell Transplantation(264), Lymphoma Diagnosis and Treatment(177), Chronic Lymphocytic Leukemia Research(171), Acute Lymphoblastic Leukemia research(146), Acute Myeloid Leukemia Research(133)

Publications600 total

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia
JCO Precision Oncology·2025Open Access
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment
Cytotherapy·2025
Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.
Blood·2025Open Access
Optimizing essential, complex hematologic care for patients living with disabilities
Blood·2025
Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia
Blood·2025Open Access
Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring
Blood·2025Open Access
Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
Transplantation and Cellular Therapy·2025
Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial
Transplantation and Cellular Therapy·2025Open Access
Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis
Transplantation and Cellular Therapy·2025· 1 cited
Safety of Addition of Inotuzumab Ozogamicin to One Alkylator-Containing Reduced-Intensity Conditioning Regimen in Hematopoietic Cell Transplantation (HCT) for Patients with Acute Lymphoblastic Leukemia and CD22 (+) Aggressive Lymphoid Malignancies: A Prospective Trial
Transplantation and Cellular Therapy·2025
Long-Term Results of Ipilimumab Alternating with Lenalidomide in Patients with Relapsed Lymphoma Who Underwent Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2025· 1 cited
Evolution of chronic lymphocytic leukemia after allogeneic stem cell transplant
2025Open Access
A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation
Blood·2024· 2 citedOpen Access
Ten-Year Results of a Phase II Clinical Trial Evaluating Ipilimumab Plus Lenalidomide Combination after Autologous Hematopoietic Cell Transplantation in Patients with Lymphoma
Blood·2024
Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
Blood·2024· 1 citedOpen Access
Addition of Inotuzumab Ozogamicin to Melphalan Plus Fludarabine Reduced-Intensity Conditioning Regimen of Allogeneic Transplantation in Patients with Acute Lymphoblastic Leukemia and Aggressive Lymphoid Malignancies: A Phase II Prospective Trial
Blood·2024
Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis
Blood·2024Open Access
Allogeneic HCT Should Be the Referred Therapy for Richter's Transformation
Clinical Lymphoma Myeloma & Leukemia·2024
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin
Blood Cancer Journal·2024· 6 citedOpen Access
Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial
American Journal of Hematology·2024· 3 citedOpen Access
page 1 of 30Next →

Frequent Co-authors

Richard E. Champlin(38), Sergio Giralt(36), Paolo Anderlini(28), Chitra Hosing(26), Börje S. Andersson(22), Rima M. Saliba(21), Marcos de Lima(19), Daniel R. Couriel(17), James Gajewski(16), Donna Przepiorka(13), Cindy Ippoliti(12), Michèle L. Donato(12), Naoto T. Ueno(12), Gabriela Rondón(11), Martin Körbling(10), Elizabeth J. Shpall(9), Koen van Besien(8), Anas Younes(8), Muzaffar H. Qazilbash(8), Rakesh Mehra(7)